Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806617) titled 'Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
Primary Sponsor: Rush University Medical Center
Condition:
Warts
Verruca (Warts)
Verruca Vulgaris
Intervention:
Biological: 9-valent human papillomavirus vaccine
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 2, 2025
Target Sample Size: 55
Countries of Recruitment:
United States
To know more, visit https://clinic...